To assess the effect of ticlopidine on the cutaneous circulation, 25 patients with lower limb ischemia were investigated just before and at two hours after being given a 200 mg oral dose of ticlopidine. The transcutaneous partial pres sure of oxygen (PtcO2) and the skin temperature were determined at 35 limb sites and 9 chest walls sites. Both the PtcO 2 and the skin temperature were significantly increased at two hours after the administration of ticlopidine (p < 0.01). The findings suggest that ticlopidine can improve the cutaneous mi crocirculation in patients with peripheral vascular disease.
Get full access to this article
View all access options for this article.
References
1.
Yamamoto T.: Qualitative and quantitative evaluation of peripheral circulation of the leg in chronic arterial occlusive disease. J Jpn CollAngiology26:1127-1134, 1986.
2.
Ameli FM, Byrne P., Provan JL: Selection of amputation level and prediction of healing using transcutaneous tissue oxygen tension (PtcO2). J Cardiovasc Surg30:220-224, 1989.
3.
Clyne Cac, Ryan J., Webster Jhh, et al: Oxygen tension on the skin of ischemic legs. Am J Surg143:315-318, 1982.
4.
Caspary L., Creutzig A., Alexander K.: Reaction of transcutaneous PO2 and laser Doppler flow signal on intraarterial infusion of PGE, and nucleotide phosphates with peripheral arterial occlusive disease. VASA17(suppl):17-22, 1987.
5.
Iwai T., Qian SX, Muraoka Y., et al: Therapeutic effects of the stable prostacycline derivative Iroprost on chronic arterial occlusive disease of the extremities— study on percutaneous oxygen partial pressure and dermal temperature. Gendai-Iryo22(suppl 1): 144-152, 1990.
6.
Ito K., Ogi S., Tanaka K., et al: Improvement of peripheral circulation by the synthetic antithrombin agent MD-805. Gendai-Iryo29:122-126, 1987.
7.
Hirai M., Nakayama R.: Administration of PGE, and the steal phenomenon in ischemic legs—thermographic study. Kekkan8:153-160, 1985.
8.
Ashida SI, Abiko Y.: Inhibition of platelet aggregation by a new agent, Ticlopidine. Thromb Hemocytes40:542-550, 1978.
9.
Ashida SI, Abiko Y.: Mode of action of ticlopidine in inhibition of platelet aggregation in the rat. Thromb Haemostas41:436-449, 1979.
10.
Matsumoto Y. , Iwai K.: Study on the mechanism of action of ticlopidine . Medical Consultation and New Remedies26:9(2075)-36(2102), 1989.
11.
Caimi G., Lo Presti R, Serra A., et al: Red cell filterability and erythrocyte membrane microviscosity during ticlopidine treatment. J Int Med Res18:161-163, 1990.
12.
Yamaguchi H. , Nagata T., Nagata K., et al: Action of ticlopidine on erythrocyte deformability in peripheral occlusive arterial disease. J Jpn CollAngiology27:942, 1987.
13.
Di Minno G, Cerbone AM, Mattioli PL, et al: Functionally thrombasthenic state in normal platelets following the administration of ticlopidine . J Clin Invest75:328-338, 1985.
14.
Schror K., Braun M.: Platelets as a source of vasoactive mediators. Stroke21:IV32-35, 1990.
15.
Balsano F., Coccheri S., Libretti A., et al: Ticlopidine in the treatment of intermittent claudication: A 21-month double-blind trial. J Lab Clin Med114:84-91, 1989.
16.
Katsumura T. , Masaki H., Fukuda H., et al: Peripheral circulatory disorders. Geka51:474-477, 1989.
17.
McTavish D. , Faulds D., Goa KL: Ticlopidine. An updated review of its pharmacology and therapeutic use in platelet-dependent disorders . Drugs40:238-259, 1990.
18.
Sakurai T., Sionoya K., Ueyama T., et al: Clinical effect of antiplatelet agents on graft patency following vascular reconstruction in the lower extremity. J Jpn CollAngiology29:1141-1143, 1989.
19.
Shimizu H., Kihana H., Tajima S., et al: Objective evaluation of the effects of drugs on Raynaud's symptoms— measurement of dermal blood flow and platelet aggregation by a laser Doppler flowmeter. Dermatol97:35-38, 1987.
